Asciminib is the first generation targeted therapy drug

Asciminib (Asciminib) is a new type of targeted therapy drug and belongs to the third generation of targeted therapy drugs. It is primarily used to treat patients with chronic myeloid leukemia (CML), especially those who have developed resistance to first- and second-generation tyrosine kinase inhibitors (TKIs). As a breakthrough drug, Aceminib is of great significance in the field of targeted therapy.

Aximini's mechanism of action is different from otherTKIs drugs. Most TKIs drugs treat by inhibiting the tyrosine kinase activity produced by the BCR-ABL fusion geneCML, while Aceminib selectively inhibits the specific domain of BCR-ABL——Myristoyl-Binding Pocket(MBP), which gives Aceminib unique advantages in the treatment of CML. Its mechanism difference from other TKIs makes it more effective in treating drug-resistant CML patients.

Third-generation targeted drugs generally have greater selectivity and fewer side effects than first- and second-generation targeted drugs. Through its unique mechanism of action, Asiminib can effectively overcome some TKI resistance mutations, especially for CML patients with the T315I mutation. This mutation usually leads to the failure of other targeted drugs, so Asiminib provides a new treatment option.

Although aximini is a third-generation targeted drug, its time on the market is relatively short. Currently, the approval and use of aceminib in many regions around the world is still in the stage of gradual promotion, especially in some CML patient groups. For patients with treatment-resistant CML, aceminib provides a new treatment option and may become one of the standard treatments for chronic myelogenous leukemia in the future.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib